BUD APAC (01876) announced its annual performance for the year 2025, with net profit attributable to equity holders decreasing by 32.6% to 489 million US dollars compared to the previous year.
AB InBev Asia Pacific (01876) announced its annual performance for the year ended December 31, 2025, with revenue of 5.764 billion US dollars, a decrease of 7.7% year-on-year; net profit attributable to shareholders of AB InBev Asia Pacific was 489 million US dollars, a decrease of 32.6% year-on-year; basic earnings per share were 3.70 US cents.
BUD APAC (01876) announced its financial results for the year ending December 31, 2025, with revenue of $5.764 billion, a decrease of 7.7% compared to the previous year. The net profit attributable to BUD APAC shareholders was $489 million, a decrease of 32.6% compared to the previous year. Earnings per share were $0.037.
Total sales for the full year of 2025 decreased by 6.0%, primarily due to the company's business operations in China, partially offset by performance in India.
In the 2025 financial year, revenue decreased by 6.1%, or by 7.7% according to the reporting standard, and revenue per hectoliter decreased by 0.2%. This was mainly due to the company's performance in China, partially offset by revenue management measures in the East Asia Pacific region and positive performance in India.
In the fourth quarter of 2025, the company's sales and market share in China remained stable, consistent with the industry trend of slower performance due to delayed Lunar New Year shipping arrangements. As the company increased its investment in channel and product portfolio expansion, the brand impact of Budweiser increased, putting additional pressure on profit for the quarter. In South Korea, the company performed better than market levels in both on-trade and off-trade channels, with overall net revenue per hectoliter continuing to grow. In India, the company's premiumization strategy made progress, achieving strong double-digit revenue growth and expanding overall market share.
CEO and Co-Chairman Yanjun Cheng said, "In 2025, we have not fully realized the potential in China. We have taken clear actions to strengthen management in the off-trade channel, enrich the product portfolio, and launch innovative products under flagship brands to reshape and ignite growth. In South Korea and India, we continue to increase market share and improve profit before tax, interest, depreciation, and amortization. As we enter 2026, we have established a clear strategy and strengthened execution to leverage our capabilities and achieve sustainable long-term growth. Therefore, I am pleased to announce that the board has recommended a dividend of $0.566 per share for the 2025 financial year, consistent with 2024."
Related Articles

XINHUA LANDE (08106) will be suspended from trading from February 12th.

GLOBAL NEW MAT (06616) resumed trading on February 12th.

GUANZE MEDICAL (02427) will resume trading on February 12th.
XINHUA LANDE (08106) will be suspended from trading from February 12th.

GLOBAL NEW MAT (06616) resumed trading on February 12th.

GUANZE MEDICAL (02427) will resume trading on February 12th.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


